Covidien Surgical Stapler Class Action Lawsuit Filed Over Life-Threatening Infections in Canada

Similar complaints have been filed in the U.S. over Covidien surgical stapler failures, as well as failures by surgical staplers from other manufacturers.

Medtronic and its Covidien subsidiary face a surgical stapler class action lawsuit in Canada, raising allegations that mirror similar claims presented throughout the U.S. court system, indicating that stapler defects and failures have led to life-threatening infections and other adverse health complications.

According to a report by CTVNews published late last month, Health Canada has received more than 1,100 reports of surgical stapler malfunctions, which have led to several class action lawsuits in that country.

One complaint, filed by Angelo Paolozzi indicates staples used on his bowels after a diverticulitis surgery failed, resulting in a life-threatening infection that left him hospitalized for a month.

Another class action complaint, filed in British Columbia by Lois Ruscheinski, came after Ruscheinski nearly died of internal bleeding after a staple line in her bowel failed, resulting in her bleeding from multiple wounds which led to her being hospitalized for several days.

The complaints join a growing number of similar surgical stapler lawsuits being filed here in the U.S. as well in recent years, all claiming Covidien and other manufacturers designed defective products which have been plagued by recalls and numerous reports of surgical complications.

Learn More About

Surgical Staplers Lawsuits

Problems with surgical staplers may result in devastating injuries from internal surgery staples. Lawyers review cases nationwide.


In March 2019, the FDA reported that at least 41,000 adverse event reports involving problems with surgical staplers were filed with U.S. regulators between January 2011 and March 2018, including 366 patient deaths. The next month, the FDA proposed new rules and guidelines designed to make surgical staplers safer, and to classify them as moderate risk medical devices.

As part of an effort to increase the safety of surgical staplers, the FDA announced last year that it had finalized new rules and guidelines for manufacturers, including a decision to reclassify staplers as Class II surgical devices, which now requires any new surgical staplers to undergo premarket review before getting FDA approval.

The change of surgical staplers from class I medical device (general controls) to class II medical devices (special controls) has been anticipated for several years, and does not affect the classification of the staples themselves. However, it would require more stringent premarket approval for new staplers and force manufacturers to provide more thorough safety warnings and instructions.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted 2 days ago)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 4 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.